This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Boehringer Ingelheim denied preliminary injunction against Zentiva by UPC

By Inbar Preiss ( May 9, 2025, 13:29 GMT | Insight) -- Boehringer Ingelheim International has seen the Unified Patent Court reject a request for provisional measures against Zentiva related to its generic nintedanib medicines used to treat lung fibrosis and cancer. The Lisbon Local Division found no imminent risk of patent infringement and held that Zentiva’s administrative steps in Portugal did not amount to concrete plans for market entry before the patent’s expiry in April next year.Boehringer Ingelheim International has been denied provisional measures at the Unified Patent Court against Zentiva related to its generic nintedanib medicines used to treat lung fibrosis and cancer....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections